Relay Therapeutics, Inc. (RLAY) Stock Price & Analysis
Relay Therapeutics, Inc. (RLAY) rose 3.15% to USD 14.09 as of June 10, 2026 at 00:51 UTC, according to Nexqual real-time market data.
RLAY last closed at USD 13.66; the session ranged USD 13.19–14.14 on volume of 2,910,587 shares. Market capitalization is $3.07B, with a 52-week range of USD 2.98–17.47 (NGM). Source: Nexqual, June 10, 2026 at 00:51 UTC.
Key Statistics (as of June 10, 2026 at 00:51 UTC)
| Price | USD 14.09 |
|---|---|
| Change | ▲ 3.15% (up) |
| Previous Close | USD 13.66 |
| Open | USD 13.99 |
| Day Range | USD 13.19 – 14.14 |
| 52-Week Range | USD 2.98 – 17.47 |
| Volume | 2,910,587 shares |
| Market Cap | $3.07B |
| Exchange | NGM |
Technical Analysis (RLAY)
Nexqual's technical model rates RLAY "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:51 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 46.81 (neutral) |
| vs SMA50 | Above (USD 13.76) |
| MACD | 0.28 (positive) |
Analyst Ratings (RLAY)
Wall Street analysts rate RLAY "Strong Buy" based on 12 analysts, with a mean price target of USD 24.25 (range USD 18–32), per Nexqual as of June 10, 2026 at 00:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 24.25 |
| High Target | USD 32 |
| Low Target | USD 18 |
| Buy / Hold / Sell | 13 / 0 / 0 |
Earnings (RLAY)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD -0.4 |
| Revenue Estimate | $645,450 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.41 vs est -0.36 ▼ miss |
| 2025-12-31 | USD -0.31 vs est -0.4 ▲ beat |
| 2025-09-30 | USD -0.43 vs est -0.42 ▼ miss |
| 2025-06-30 | USD -0.41 vs est -0.47 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financials & Fundamentals (RLAY)
| Total Revenue | $10.68M |
|---|---|
| Revenue Growth (YoY) | -60.90% |
| Gross Margin | +0.00% |
| Operating Margin | -2619.67% |
| Profit Margin | +0.00% |
| ROE | -40.01% |
| Debt / Equity | 4.92 |
| Current Ratio | 22.13 |
| Total Cash | $642.07M |
| Total Debt | $31.57M |
| Free Cash Flow | $-121.18M |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Financial Health Score (RLAY)
Nexqual rates Relay Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:51 UTC.
| Growth | Strong — Revenue +53% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $642M cash vs $32M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$121M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -24.7% |
Ownership (RLAY)
| Insider Ownership | +1.39% |
|---|---|
| Institutional Ownership | +86.98% |
| Shares Outstanding | 217.94M |
| Float | 136.02M |
| Short % of Float | +18.39% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
Leadership (RLAY)
Relay Therapeutics, Inc. is led by Sanjiv K. Patel M.A., M.B.A., M.D., MBBS (age 51), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:51 UTC.
| CEO, President & Director | Sanjiv K. Patel M.A., M.B.A., M.D., MBBS (age 51) |
|---|---|
| Founder & Independent Director | Mark Murcko (age 65) |
| Chief Financial Officer | Thomas Catinazzo (age 48) |
| President of Research & Development | Donald A. Bergstrom (age 53) |
| Chief Scientific Officer | Jim Watters |
Major Backers & Investors (RLAY)
Notable institutional backers of Relay Therapeutics, Inc. include SB Investment Advisers (UK) LTD, Commodore Capital Lp, Casdin Capital, LLC, according to Nexqual as of June 10, 2026 at 00:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| SB Investment Advisers (UK) LTD | 14.57% |
| Commodore Capital Lp | 8.87% |
| Casdin Capital, LLC | 7.53% |
| Perceptive Advisors Llc | 5.09% |
| Bellevue Group AG | 4.07% |
| Nextech Invest, Ltd. | 2.88% |
| TCG Crossover Management, LLC | 2.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.65% |
| Vanguard Group | 7.62% |
| State Street | 4.88% |
Source: Nexqual, June 10, 2026 at 00:51 UTC.
From Relay Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
- It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
- The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases.
- It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| NRIX | Nurix Therapeutics, Inc. | USD 15.64 | ▲ 6.83% |
| RVMD | Revolution Medicines, Inc. | USD 149.55 | ▲ 0.21% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:51 UTC. This page is informational and not investment advice.